Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421051 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1ADRB2HIF1ATSHR | |
| SCHEMBL3672484 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1ADRB2HIF1ATSHR | |
| SCHEMBL11372834 | 0.85 | AOC3 (0.58) | KDM4EL3MBTL1LMNAKMT2ACYP2D6 | |
| Fepradinol SCHEMBL151235 | 0.83 | KDM4E (0.55) | KDM4EL3MBTL1ADRB2LMNAKMT2A | |
| SCHEMBL21616540 | 0.83 | ADRB2 (0.58) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL30534867 | 0.82 | HIF1A (0.68) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL28319296 | 0.82 | ADRB2 (0.58) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL6464765 | 0.82 | HIF1A (0.68) | KDM4EADRB2HIF1ATSHRLMNA | |
| Fepradinol SCHEMBL29454386 | 0.82 | KDM4E (0.53) | KDM4EL3MBTL1ADRB2LMNAKMT2A | |
| SCHEMBL12205817 | 0.81 | HRH1 (0.52) | ADRB2HIF1ACYP2D6ADRB1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9862715-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2419213-B1 | BICYCLIC ORGANOSILICON COMPOUNDS AS ELECTRON DONORS FOR POLYOLEFIN CATALYSTS | FORMOSA PLASTICS CORP USA (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-08 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2083920-B1 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE | WEI EDWARD TAK (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100041757-A1 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE | WEI EDWARD TAK | 2010-02-18 | — | — | US | disclosed |
| EP-2083920-A1 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE | Wei, Edward T. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7495028-B2 | R-bambuterol, its preparation and therapeutic uses | TAN, WEN, DR. | 2009-02-24 | — | — | US | disclosed |
| US-20080118558-A1 | N-Arylshydroxyalkylidene carboxamide compositions and methods | WEI EDWARD T | 2008-05-22 | — | — | US | disclosed |
| WO-2008056118-A1 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE | PAGET, HUGH, CHARLES, EDWARD (GB) | 2008-05-15 | — | — | WO | disclosed |
| US-20070155755-A1 | N-arylshydroxyalkylidene-carboxamide compositions and methods | WEI EDWARD T | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | KDM4E 1043/4885L3MBTL1 2640/4885ADRB2 1888/4885 |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885L3MBTL1 1470/4885ADRB2 4577/4885 |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | KDM4E 1043/4885L3MBTL1 2640/4885ADRB2 1888/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885L3MBTL1 1470/4885ADRB2 4577/4885 |
| US-20080118558-A1 | N-Arylshydroxyalkylidene carboxamide compositions and methods | TRPV1, OPRL1, HRH2 | KDM4E 1668/4885L3MBTL1 4503/4885ADRB2 782/4885 |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK3 | KDM4E 307/4885L3MBTL1 944/4885ADRB2 2886/4885 |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | KDM4E 177/4885L3MBTL1 1642/4885ADRB2 3332/4885 |
| US-20070155755-A1 | N-arylshydroxyalkylidene-carboxamide compositions and methods | TRPV1, OPRL1, HRH2 | KDM4E 1772/4885L3MBTL1 4521/4885ADRB2 618/4885 |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | IRAK4, IRAK1, IRAK3 | KDM4E 307/4885L3MBTL1 944/4885ADRB2 2886/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | KDM4E 1043/4885L3MBTL1 2640/4885ADRB2 1888/4885 |
| US-20100041757-A1 | N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE | TRPV1, TRPA1, TRPV2 | KDM4E 1309/4885L3MBTL1 4119/4885ADRB2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.